Arbutus Biopharma Corp expected to post a loss of 10 cents a share - Earnings Preview

Arbutus Biopharma

28/04/2025 12:41

Arbutus Biopharma Corp ABUS.OQ ABUS.O is expected to show a rise in quarterly revenue when it reports  results on April 30 (estimated) for the period ending March 31 2025

The Warminster Pennsylvania-based  company is expected to report a 16.1% increase in revenue to $1.779 million from $1.53 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Arbutus Biopharma Corp is for a loss of 10 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Arbutus Biopharma Corp is $5.00​, above​ its last closing price of $3.29. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.08
-0.07
Beat
12.5
Sep. 30 2024
-0.09
-0.09
-0.09
Met
4.9
Jun. 30 2024
-0.09
-0.10
-0.11
Missed
-13.6​
Mar. 31 2024
-0.11
-0.11
-0.10
Beat
9.1
​​Dec. 31 2023
-0.12
-0.12
-0.12
Met
-1.7
Sep. 30 2023
-0.11
-0.11
-0.12
Missed
-5.4​
Jun. 30 2023
-0.11
-0.11
-0.10
Beat
10.9
Mar. 31 2023
-0.14
-0.14
-0.10
Beat
26.5

This summary was machine generated April 28 at 11:41 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)